**Author details**

Victoria Moreno-Manzano1 and Elisa Oltra García2,3\*

\*Address all correspondence to: elisa.oltra@ucv.es

1 Cellular Reprogramming Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain

2 School of Medicine, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain

[9] Anderson RH, Francis KR. Modeling rare diseases with induced pluripotent stem cell technology. Molecular and Cell Probes. 2018;**40**:52-59. DOI: 10.1016/j.mcp.2018.01.001 [10] Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature

Culturing Adult Stem Cells for Cell-Based Therapeutics: Neuroimmune Applications

http://dx.doi.org/10.5772/intechopen.80714

127

[11] Ahuja CS, Wilson JR, Nori S, Kotter MRN, Druschel C, Curt A, et al. Traumatic spinal cord injury. Nature Reviews Disease Primers. 2017;**3**:17018. DOI: 10.1038/nrdp.2017.18

[12] Kwon BK, Liu J, Messerer C, Kobayashi NR, McGraw J, Oschipok L, et al. Survival and regeneration of rubrospinal neurons 1 year after spinal cord injury. Proceedings of the National Academy of Sciences of the United States of America. 2002;**99**(5):3246-3251 [Epub

[13] Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000;**403**(6768):

[14] Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nature Medicine.

[15] Cafferty WB, Duffy P, Huebner E, Strittmatter SM. MAG and Omgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma.

[16] DeBellard ME, Tang S, Mukhopadhyay G, Shen YJ, Filbin MT. Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a

[17] Barton WA, Liu BP, Tzvetkova D, et al. Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. The EMBO Journal. 2003;**22**(13):3291-3302

[18] McKeon RJ, Schreiber RC, Rudge JS, Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. The Journal of Neuroscience. 1991;**11**(11):33983411 [19] Woolfe F, Waxman SG, Hains BC. In silico modeling of axonal reconnection within a discrete fiber tract after spinal cord injury. Journal of Neurotrauma. 2007;**24**(2):421-432

[20] Dietz V, Curt A. Neurological aspects of spinal-cord repair: Promises and challenges.

[21] Friedli L, Rosenzweig ES, Barraud Q, Schubert M, Dominici N, Awai L, et al. Pronounced species divergence in corticospinal tract reorganization and functional recovery after lateralized spinal cord injury favors primates. Science Translational Medicine.

[22] Assinck P, Duncan GJ, Hilton BJ, Plemel JR, Tetzlaff W. Cell transplantation therapy for spinal cord injury. Nature Neuroscience. 2017;**20**(5):637-647. DOI: 10.1038/nn.4541

sialoglycoprotein. Molecular and Cellular Neurosciences. 1996;**7**(2):89-101

Biotechnology. 2008;**26**(11):1276-1284. DOI: 10.1038/nbt.1503

The Journal of Neuroscience. 2010;**30**(20):6825-6837

Lancet Neurology. 2006;**5**(8):688-694

2015;**7**(302):302ra134. DOI: 10.1126/scitranslmed.aac5811

Feb 26, 2002]

2006;**12**(7):790-792

434-439

3 Unidad Mixta CIPF-UCV, Centro de Investigación Príncipe Felipe, Valencia, Spain
